As EGFR and HGFR were highly activated in pediatric brain tumors[5] and subsequently high percentages of pediatric brain tumor cells expressed these RTKs, these findings could provide a rational explanation of the limited efficacy of single targeted treatment in clinical trials. The gene discussed is EGFR; the disease is brain neoplasm.